Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Edwards Lifesciences
(NY:
EW
)
85.78
+1.52 (+1.80%)
Official Closing Price
Updated: 7:00 PM EDT, Mar 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Edwards Lifesciences
< Previous
1
2
...
15
16
17
18
19
20
21
22
Next >
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
↗
January 23, 2022
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...
Via
Benzinga
$100 Invested In This Stock 10 Years Ago, Would Be Worth This Much
↗
January 10, 2022
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 10 years by 12.27% on an annualized basis. Buying $100 In EW: 10 years ago, an investor could have...
Via
Benzinga
Where Edwards Lifesciences Stands With Analysts
↗
January 07, 2022
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW)...
Via
Benzinga
CNBC's Final Trades: Match Group, PayPal, Edwards Lifesciences And This Hospitality Major
↗
December 23, 2021
On CNBC’s “Halftime Report Final ...
Via
Benzinga
Edwards Lifesciences Corp. (EW) Looks to Continue to Trade Above its Annual-High Share Price Today
December 22, 2021
Via
Investor Brand Network
Watch for Continued Gains in Shares of Edwards Lifesciences Corporation (EW)
December 17, 2021
Via
Investor Brand Network
Expert Ratings For Edwards Lifesciences
↗
October 28, 2021
Edwards Lifesciences (NYSE:EW) has observed the following analyst ratings withi...
Via
Benzinga
Earnings Scheduled For October 27, 2021
↗
October 27, 2021
Companies Reporting Before The Bell • McDonald's (NYSE:MCD) is expected to report quarterly earnings at $2.46 per share on revenue of $6.03 billion. • General...
Via
Benzinga
Jim Cramer Shares His Thoughts On Medtronic, Peloton Interactive And More
↗
December 20, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Duluth Holdings Inc. (NASDAQ:
Via
Benzinga
Watch for Continued Gains in Shares of Edwards Lifesciences Corporation
↗
December 17, 2021
Edwards Lifesciences Corporation (NYSE: EW) traded at a new 12-month high today of $123.56. So far today approximately 1.6 million shares have been exchanged, as compared to an...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
↗
December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021
↗
December 17, 2021
Upgrades According to Morgan Stanley, the prior rating for Definitive Healthcare Corp (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Wednesday
↗
December 15, 2021
Barclays boosted the price target on Sysco Corporation (NYSE:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021
↗
December 10, 2021
Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Friday
↗
December 10, 2021
Keybanc boosted the price target on Broadcom Inc. (NASDAQ:
Via
Benzinga
Where Edwards Lifesciences Stands With Analysts
↗
December 09, 2021
Analysts have provided the following ratings for Edwards Lifesciences (NYSE:EW)...
Via
Benzinga
10 Biggest Price Target Changes For Thursday
↗
December 09, 2021
SVB Leerink boosted the price target on Edwards Lifesciences Corporation (NYSE:
Via
Benzinga
Notable Edwards Lifesciences Insider Trades $4.9M In Company Stock
↗
November 10, 2021
Michael Mussallem, Chairman And CEO at Edwards Lifesciences (NYSE:EW), made a large buy and sell of company shares on November 9, according to a new SEC filing. What Happened: A...
Via
Benzinga
Topics
Regulatory Compliance
Edwards' Transcatheter Tricuspid Replacement System Shows Favorable Patient Outcomes
↗
November 08, 2021
Edwards Lifesciences Corporation (NYSE: EW) announced results from the TRISCEND study of its EVOQUE transcatheter tricuspid valve replacement system. Patients...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
↗
December 06, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX:
Via
Benzinga
Edwards Lifesciences Says Delta Variant Drove Procedure Deferrals In Q3
↗
October 28, 2021
Edwards Lifesciences Corp (NYSE: EW) reported Q3 earnings of $340.1 million, or $0.54 per share, ahead of the consensus of $0.53. Sales grew 15% to $1.31 billion;...
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
↗
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
Edwards Lifesciences Corporation (EW) Q3 2021 Earnings Call Transcript
↗
October 27, 2021
EW earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Recap: Edwards Lifesciences Q3 Earnings
↗
October 27, 2021
Edwards Lifesciences (NYSE:EW) reported its Q3 earnings results on Wednesday, October 27, 2021 at 04:15 PM. Here's what investors need to know about the announcement. Earnings...
Via
Benzinga
Edwards Topples As Full-Year Guidance Comes In Light After Mixed Quarter
↗
October 27, 2021
The company retained guidance for adjusted profit of $2.07-$2.27, missing the midpoint of analysts' view.
Via
Investor's Business Daily
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
↗
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
Notable Edwards Lifesciences Insider Trades $4.6M In Company Stock
↗
October 04, 2021
Michael Mussallem, Chairman And CEO at Edwards Lifesciences (NYSE:EW), made a large buy and sell of company shares on October 1, according to a new SEC filing. What Happened: A...
Via
Benzinga
Topics
Regulatory Compliance
Insider Development Of Edwards Lifesciences Trades $1.59 Million In Company Stock
↗
September 13, 2021
Donald Bobo Jr, insider at Edwards Lifesciences (NYSE:EW), made a large buy and sell of company shares on September 10, according to a new SEC filing. What Happened: A Form 4...
Via
Benzinga
Topics
Regulatory Compliance
Notable Edwards Lifesciences Insider Trades $1.39 Million In Company Stock
↗
September 09, 2021
Catherine Szyman, Insider at Edwards Lifesciences (NYSE:EW), made a large buy and sell of company shares on September 8, according to a new SEC filing. What Happened: A Form...
Via
Benzinga
Topics
Regulatory Compliance
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
↗
September 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:...
Via
Benzinga
< Previous
1
2
...
15
16
17
18
19
20
21
22
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.